When was LaCAR MDX Technologies founded?

LaCAR MDX Technologies was founded in 2013.

Where is LaCAR MDX Technologies located?

LaCAR MDX Technologies is headquartered in Liege, Belgium.

How many employees does LaCAR MDX Technologies have?

As of Apr 30, 2026, the latest employee count at LaCAR MDX Technologies is 66.

Is LaCAR MDX Technologies a funded company?

LaCAR MDX Technologies is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does LaCAR MDX Technologies rank among its competitors?

LaCAR MDX Technologies ranks 34th amongst 33 active competitors, of which 7 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Oncobit, which secured $2.36M in Dec, 2025.

Who are the top competitors of LaCAR MDX Technologies?

LaCAR MDX Technologies' top competitors include Oncobit, Genedrive and C3J Therapeutics. Among them, Oncobit secured the most recent funding round in December, 2025.

LaCAR MDX Technologies - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

LaCAR provides an isothermal amplification based PCR machine called LC-Genie which work on LAMP technology principle. The company also offers several diagnostic kits compatible with the system namely genetic thrombosis kit, hemochromatosis kit, and sickle cell disease kit. Additionally, the company also manufactures certain standard accessories for the test LC-genie strip, LC-strip holder, and LC-centrifuge.

Website: www.lacar-mdx.com/en/
Social
Email ID: *****@lacar-mdx.com
Phone Number: +32 **********

Key Metrics

Founded Year

2013

Location

Liege, Belgium

Stage

Funding Raised

Investors

Noshaq

Ranked

34^th among 45 competitors

Employee Count

66 as on Apr 30, 2026

Similar Companies

Oncobit & 43 more

View LaCAR MDX Technologies' full profile

LaCAR MDX Technologies is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LACAR MDX TECHNOLOGIES CIN: 0543.330.355 , Belgium, Active	Dec 16, 2013	-	25 (As on Dec 31, 2022)	-

LaCAR MDX Technologies is a funded company. LaCAR MDX Technologies has 1 institutional investor.

View details of LaCAR MDX Technologies's funding rounds and investors

The founders of LaCAR MDX Technologies is Arnaud Allaer.

Here are the details of LaCAR MDX Technologies' key team members:

Arnaud Allaer: Founder of LaCAR MDX Technologies.

View details of LaCAR MDX Technologies's Founder profiles and Board Members

LaCAR MDX Technologies' employee count trend

LaCAR MDX Technologies has 66 employees as of Apr 26. Here is LaCAR MDX Technologies's employee count trend over the years:

Employee count trend for LaCAR MDX Technologies

Uncover LaCAR MDX Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LaCAR MDX Technologies include Oncobit, Genedrive and C3J Therapeutics. Here is the list of Top 10 competitors of LaCAR MDX Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Oncobit 2018, Zurich (Switzerland), Series A	Developer of diagnostic and monitoring tests for precision treatment	$6.58M	Swiss ICT Investor Club, AVANTECA & 2 others	52/100
2nd	Genedrive 2000, Manchester (United Kingdom), Public	Provider of point of care molecular diagnostics platform for genotyping and sequence analysis	-	Global Health Investment Fund, Calculus Capital	49/100
3rd	C3J Therapeutics 2006, Los Angeles (United States), Series D	Developing phage therapeutics to combat antibiotic-resistant bacterial infections	$154M	Renaissance Acquisition Holdings, HHS & 1 others	48/100
4th	InDex Pharmaceuticals 2000, Stockholm (Sweden), Public	DNA-based immunomodulatory sequence medication for the treatment of inflammtatory bowel disease.	$45.4M	Industrifonden, SEB & 5 others	46/100
5th	Molecular Designs 2019, Birmingham (United States), Funding Raised	Developer of molecular diagnostic kits for the detection of a wide range of diseases	-	Excellere Partners	41/100
6th	Qantgene 2015, Berkeley (United States), Series B	Provider of cancer screening blood test for early detection	$12.1M	Vikor Scientific, StartUp Health	40/100
7th	Beijing Rubber Xin Biological Technology 2017, Haidian (China), Series B	Developer of tumor genetic testing reagents and instruments	$28.7M	Yikai Venture Capital, Leading Capital Group ... & 4 others	38/100
8th	Galaxy Diagnostics 2009, Durham (United States), Series A	PCR-based Human and Animal testing for vector-borne diseases	$6.72M	First Flight Venture Center, HHS	37/100
9th	Genturadx 2005, Hayward (United States), Acquired	Molecular diagnostic platforms for clinical applications	$4.01M	Bay City Capital	32/100
10th	SensID 2015, Rostock (Germany), Acquired	Developer of reference materials for DNA diagnostic applications	-	GENIUS Venture Capital	30/100
34th	LaCAR MDX Technologies 2013, Liege (Belgium), Funding Raised	Developer of kits and instruments for IVD	-	Noshaq	20/100